SYDNEY, Australia, Feb. 16, 2026 — Clarity Pharmaceuticals announced new clinical data from the Co-PSMA Investigator-Initiated Trial demonstrating that Cu-64 SAR-bisPSMA PET/CT imaging more than doubled prostate cancer lesion and patient detection rates compared with standard-of-care Ga-68 PSMA-11. The findings, accepted for oral presentation at the European Association of Urology (EAU) Congress 2026, highlight the growing clinical impact of next-generation radiopharmaceutical diagnostics in detecting recurrent prostate cancer at low PSA levels.
Science Significance
The Phase II Co-PSMA trial evaluated diagnostic performance in 50 patients experiencing biochemical recurrence (BCR) following radical prostatectomy, a clinical setting where early lesion detection is critical yet technically challenging. Results showed that Cu-64 SAR-bisPSMA identified 63 lesions compared with 24 detected by Ga-68 PSMA-11, achieving the study’s primary endpoint of superior per-patient lesion detection.Mean lesion detection per patient reached 1.26 with Cu-64 SAR-bisPSMA versus 0.48 with the comparator, representing a statistically significant difference. Patient-level detection also improved dramatically, with 78% positivity versus 36% for standard imaging. These findings validate the scientific advantage of dual-targeting bisPSMA molecular design and copper-based radiotracer imaging, particularly in patients with low prostate-specific antigen levels where traditional imaging sensitivity is limited.
Regulatory Significance
Although Cu-64 SAR-bisPSMA remains an investigational radiopharmaceutical, the trial data contribute to a growing body of evidence supporting regulatory advancement. The agent has already received multiple Fast Track Designations from the U.S. FDA across its clinical development program, reflecting its potential to address unmet diagnostic needs.Ongoing registrational trials, including AMPLIFY and CLARIFY, are expected to support future regulatory submissions. As radiopharmaceutical imaging agents require rigorous evaluation across safety, dosimetry, manufacturing, and diagnostic accuracy endpoints, positive comparative trials such as Co-PSMA are critical for progressing toward approval and clinical guideline integration.
Business Significance
Advertisement
From a commercial perspective, the data position Clarity Pharmaceuticals competitively within the rapidly expanding PSMA PET imaging market, currently valued at approximately $2 billion annually and projected to grow significantly. Demonstrated superiority over widely used tracers such as Ga-68 PSMA-11 may offer meaningful differentiation in a crowded diagnostic landscape.Clarity’s proprietary SAR chelation technology, designed to securely bind copper isotopes and prevent systemic leakage, also represents a strategic intellectual property advantage. Enhanced imaging performance combined with scalable isotope logistics may strengthen the company’s commercialization pathway and partnership potential across nuclear medicine networks.
Patients’ Significance
For patients with recurrent prostate cancer, improved imaging sensitivity has profound clinical implications. Early detection of metastatic or localized recurrence enables timely salvage therapy, targeted radiation planning, and avoidance of unnecessary systemic treatment.In the trial, imaging findings influenced clinical decision-making in 44% of participants, demonstrating direct impact on treatment planning. More accurate lesion localization supports personalized care pathways, potentially improving survival outcomes while reducing treatment toxicity and healthcare burden.
Policy Significance
The advancement of high-sensitivity radiopharmaceutical imaging aligns with healthcare policy priorities surrounding precision oncology diagnostics and early intervention strategies. As imaging technologies evolve, policymakers and payers must consider reimbursement frameworks that reflect the long-term value of earlier and more accurate disease detection.Improved diagnostic performance may also influence prostate cancer management guidelines, supporting broader adoption of PSMA PET imaging in recurrence settings and reinforcing the role of nuclear medicine within integrated cancer care pathways.
The Co-PSMA trial results underscore the transformative potential of Cu-64 SAR-bisPSMA as a next-generation prostate cancer imaging agent. By demonstrating markedly superior lesion and patient detection compared with standard PSMA tracers, the study reinforces the clinical value of advanced radiopharmaceutical diagnostics in guiding treatment decisions. As registrational trials progress and regulatory pathways advance, copper-based theranostic imaging platforms may redefine the standard of care in prostate cancer detection and management.
Source: Clarity Pharmaceuticals press release
